GlassScriptPhysician profile
Issa Abedmahmoud
NPI 1528042975
$5,809.13
in general payments reported to CMS, 2019-2025
24 companies · $421 in 2025
The $421 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $483 · 2021: $2,371 · 2022: $612 · 2023: $772 · 2024: $622 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,815.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,543.44 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $577.52 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Dexcom, INC. | $382.33 | 2020-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $345.01 | 2019-2025 | Jardiance |
| Abbott Laboratories | $324.45 | 2020-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $257.10 | 2020-2025 | Korlym |
| Merck Sharp & Dohme LLC | $248.11 | 2019-2022 | |
| Abbvie INC. | $199.03 | 2019-2021 | |
| Amgen INC. | $158.14 | 2019-2024 | Tepezza |
| Astrazeneca Pharmaceuticals LP | $132.83 | 2021-2024 | Farxiga |
| Shire North American Group INC | $129.31 | 2019 | |
| Xeris Pharmaceuticals, INC. | $109.54 | 2020-2024 | Gvoke Hypopen, Recorlev |
| Recordati_rare_diseases_inc. | $92.76 | 2021-2022 | |
| Insulet Corporation | $81.11 | 2019-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $44.96 | 2023-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $28.97 | 2025 | |
| Pfizer INC. | $25.87 | 2024 | |
| Medtronic, INC. | $24.42 | 2025 | Minimed 780g |
| Eusa Pharma (US) LLC | $20.69 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $19.60 | 2022 | |
| Ascensia Diabetes Care US INC. | $19.56 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.39 | 2021 | |
| Horizon Therapeutics Plc | $15.06 | 2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $13.93 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Issa Abedmahmoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.